Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kineta Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals sector. These actions are distributed across 3 distinct examiners and 2 distinct art units. WILLIS, DOUGLAS M is the busiest examiner, managing 2 pending actions.
This concentration of 2 actions under the busiest examiner suggests a primary point of contact for the company current prosecution. With 4 pending office actions in total, the portfolio is active across 2 distinct art units, indicating a focused but multi-faceted approach to its pharmaceutical patent filings. The use of 3 distinct examiners for the actions shows some consolidation of the workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 2 | 82.4% | +19.7% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717144 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | WILLIS, DOUGLAS M | — |
| 18717141 | PYRIMIDINES AND METHODS OF THEIR USE | WILLIS, DOUGLAS M | — |
| 18717172 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | REDWOOD, CHRISTOPHER EVAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717144 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | WILLIS, DOUGLAS M | — |
| 18717141 | PYRIMIDINES AND METHODS OF THEIR USE | WILLIS, DOUGLAS M | — |
| 18007983 | PURINES AND METHODS OF THEIR USE | HERNANDEZ, JACKSON J | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717144 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | WILLIS, DOUGLAS M | 1624 | §102§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18717141 | PYRIMIDINES AND METHODS OF THEIR USE | WILLIS, DOUGLAS M | 1624 | §102§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18717172 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | REDWOOD, CHRISTOPHER EVAN | — | §102§103§112Other | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18007983 | PURINES AND METHODS OF THEIR USE | HERNANDEZ, JACKSON J | 1627 | §103DP | Final Rejection | — | Pending | Dec 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKineta Inc. has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Douglas M Willis has the most, with 2 of Kineta Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
